- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04682847
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Adaptive Stereotactic Radiotherapy With Superparamagnetic Iron Oxide Nanoparticles (SPION) Cellular Magnetic Resonance Imaging on MR-Linac (MR-L-SPION) for Primary and Metastatic Hepatic Malignancies With Assessment of Treatment Response.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Setting/Participants:
The study will be performed at a single center - Allegheny General Hospital (AGH) in a setting of referral-based outpatients within the Allegheny Health (AHN) network.
25 patients with primary and metastatic liver tumors and hepatic cirrhosis eligible for liver SBRT will be enrolled in this study.
Study Interventions and Measures:
MRI cellular imaging of hepatic parenchyma with SPION will be performed on a 1.5T MRI (Elekta MR-Linac) on the day of radiotherapy planning. Hepatic SPION accumulation will be quantified and delineated to designate volumes for conformal avoidance on the MR-Linac during liver SBRT. This quantitative assessment will be compared to the already established methodology using CT/SPECT images developed at AGH. Treatment outcomes and toxicity due to improved conformal avoidance of functional normal liver volumes will be assessed for these patients. Dose-response of tumor and hepatic parenchyma to SBRT will be examined using MR-Linac imaging, pathologic criteria and molecular profiling of explanted livers in a subset of patients who received liver SBRT as a bridge to transplant.
Main outcome of the study:
Development and evaluation of a novel MRI-Linac based functional treatment planning platform with DICOM-compatible applications for visualization and subsequent conformal avoidance of residual, functionally active hepatic parenchyma in patients undergoing liver SBRT to primary and metastatic malignancies with the assessment of tumor and hepatic parenchyma response using MR imaging correlated with both pathologic and genomic criteria in a subset of patients receiving SBRT as a bridge to liver transplant.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients age 18-89 years
- Women of childbearing age must have a negative urine/serum pregnancy test (per standard of care) and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study Women beyond childbearing are not required to use contraception.
- Child-Pugh A or B liver function;
- Child-Pugh C liver function for transplant eligible patients only.
- Single or multinodular tumors (up to four) are permitted.
- Patients required to have more than 30% of functionally active uninvolved liver outside radiation target volume;
- No prior liver radiation, including radioembolization;
- ECOG (Eastern Cooperative Oncology Group) performance score >=2
Exclusion Criteria:
- Patients over 90 year of age
- Bilirubin x3 upper limit of normal;
- AST (aspartate aminotransferase) or ALT (alanine transaminase) x6 upper limit of normal;
- Hemoglobin less than 80 g/L;
- Patients with recurrent ascites (paracentesis q ≥2 weeks);
- Patients with history of hypersensitivity to Feraheme or any other IV iron products;
- Patients with hemochromatosis (iron overload).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Primary and metastatic liver tumors and hepatic cirrhosis
This study is a single arm prospective study that will enroll 25 patients with primary and metastatic liver tumors and hepatic cirrhosis eligible for liver SBRT who will be receiving treatment at a single center - Allegheny General Hospital.
|
This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Develop a platform to maintain liver functionality during treatment for liver cancer
Time Frame: Two Years
|
The primary goal of the study is to develop MRI-linac SPION based radiotherapy planning platform for detection and conformal avoidance of residual, functionally active hepatic parenchyma during liver SBRT for primary and metastatic hepatic malignancies in patients with hepatic cirrhosis. Treatment outcomes and toxicity due to improved conformal avoidance of functional normal liver volumes will be assessed for these patients. Progression in Child-Pugh and MELD scores, disease free survival, and overall survival (with and without liver transplant) will be evaluated via Kaplan Meier analysis. Freedom from MELD score progression will be measured against residual volumes of functionally active hepatic parenchyma defined on MRI-linac SPION via Cox proportional hazard regression models. Statistical analysis will be conducted with MedCalc version 11.3. |
Two Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Develop applications for assessing the liver functionality of those with liver cancer
Time Frame: Two Years
|
MRI and planning CT images will be co-registered using deformable image registration, and volumes with SPIO accumulation will be delineated as avoidance structures by the physician and clinical physicist. DICOM-compatible applications will be developed for contouring and quantitative assessment of functionally active volumes of hepatic parenchyma obtained from MR-Linac-SPIO images with subsequent conformal avoidance in the beam placement process during 3-D Conformal radiotherapy planning. A non-contrast enhanced liver MR images will be acquired per fraction with propagation of the previously identified avoidance volumes in the adapted plans. Follow-up MR-imaging of the patients will be obtained to assess tumor and hepatic parenchyma response treatment. |
Two Years
|
Examine the dose-response of tumor and liver tissue in patients who received liver transplant after receiving SBRT
Time Frame: Two Years
|
The dose-response of tumor and hepatic parenchyma to SBRT will be examined using MR imaging (on MR-Linac), pathologic criteria and molecular profiling of explanted livers in a subset of patients who received liver SBRT as a bridge to transplant. In patients undergoing liver transplant MRI data sets will be merged with 3D dosimetry data and evaluated by a clinical physicist. Radiographic liver responses will be compared with explant liver pathology. The pathologic and genomic analysis will document both tumor and hepatic parenchymal response to SBRT. The chronology of tumor and hepatic parenchymal response and regeneration to radiotherapy will be evaluated. Initial 3D dosimetry will be combined with the pathologic assessment to determine any dose threshold for healthy liver regeneration following SBRT with MR-Linac SPION functional imaging. |
Two Years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexander Kirichenko, MD, PhD, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Neoplastic Processes
- Fibrosis
- Carcinoma
- Carcinoma, Hepatocellular
- Neoplasm Metastasis
- Liver Cirrhosis
- Liver Neoplasms
- Hematinics
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Ferrosoferric Oxide
Other Study ID Numbers
- 2020-212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Neoplasms
-
Ethicon, Inc.Terminated
-
Ethicon, Inc.RecruitingLiver Cancer | Cancer of the Liver | Neoplasms, LiverUnited Kingdom, United States, Netherlands, Singapore, France, Germany, China, Korea, Republic of
-
Ewha Womans University Mokdong HospitalSeoul St. Mary's Hospital; Pusan National University Hospital; Chonnam National... and other collaboratorsUnknown
-
China Medical University HospitalActive, not recruitingLiver Transplant, Liver Cancer, ImmunosuppressantTaiwan
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedLiver Tumor | Evidence of Liver TransplantationChina
-
Tel-Aviv Sourasky Medical CenterCompletedPrimary Liver Tumor, Metastatic LiverIsrael
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Medical University of WarsawJagiellonian University; Medical University of Lublin; Medical University of... and other collaboratorsRecruiting
-
Beijing Immunochina Medical Science & Technology...Recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
Clinical Trials on Ferumoxytol injection
-
Transmed SolutionsNot yet recruitingCoronary Artery Disease
-
NYU Langone HealthTerminated
-
Michael IvNational Cancer Institute (NCI)WithdrawnChildhood Brain NeoplasmUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
Dartmouth-Hitchcock Medical CenterAmerican Epilepsy SocietyCompleted
-
Stanford UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingPregnancy Related | Anemia, Iron DeficiencyUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Radiological Society of North AmericaTerminatedStage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Locally Advanced Rectal CarcinomaUnited States
-
Michael IvCompletedBrain Injury | Brain Cancer | Brain Tumors | Primary Brain Neoplasm | Ischemic Cerebrovascular Accident | Central Nervous System Degenerative Disorder | Central Nervous System Infectious Disorder | Central Nervous System Vascular Malformation | Hemorrhagic Cerebrovascular AccidentUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science University; National... and other collaboratorsRecruitingPancreatic Adenocarcinoma | Familial Pancreatic Cancer | Pancreatic Intraductal Papillary-Mucinous NeoplasmUnited States
-
Bryan AllenNational Cancer Institute (NCI); Holden Comprehensive Cancer CenterActive, not recruitingGlioblastoma | Glioblastoma MultiformeUnited States